Literature DB >> 10890648

The role of tumor necrosis factor in the development of multiple organ failure in a murine model.

D Burdon1, T Tiedje, K Pfeffer, E Vollmer, P Zabel.   

Abstract

OBJECTIVE: To elucidate the role of tumor necrosis factor (TNF) in the development of multiple organ dysfunction syndrome (MODS) after zymosan-induced peritonitis in mice.
DESIGN: Prospective controlled laboratory study on zymosan-induced generalized inflammation in mice. Over < or =28 days, a single intraperitoneal administration of zymosan induced a three-phase illness in C57BL mice, rendering them very ill with MODS-like symptoms from day 7 onward. Additionally, the same experiment was performed on C57BL/6 TNF-Rc-p55 knockout mice to elucidate the role of TNF and its receptor p55.
SETTING: Animal research laboratory.
SUBJECTS: Inbred C57BL mice and C57BL p55-/- mice received a single sterile intraperitoneal injection of zymosan suspended in paraffin oil (0.75 mg/g of body weight).
MEASUREMENTS AND MAIN RESULTS: The animals were monitored for survival, condition, and body weight for < or =28 days. At 3, 7, 14, and 28 days after zymosan administration, bronchoalveolar lavage was performed and lungs and livers were extracted for isolation of RNA and histopathologic evaluation. Reverse-transcriptase-polymerase chain reaction was performed to quantify TNF-alpha messenger RNA (mRNA) in the respective organs. Both animal strains went through initial shock with a high mortality rate during the first 3 days. The C57BL mice developed MODS with typical symptoms and histopathologic results correlating with excessive TNF-alpha mRNA expression from day 7 onward. In contrast, no disease, histopathologic changes, nor TNF-alpha mRNA expression in liver or lung was found within the TNF-Rc-p55-/- mice.
CONCLUSION: Organ-derived TNF-alpha plays a crucial role in the development of MODS in this murine model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890648     DOI: 10.1097/00003246-200006000-00045

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  Evodiamine Inhibits Zymosan-Induced Inflammation In Vitro and In Vivo: Inactivation of NF-κB by Inhibiting IκBα Phosphorylation.

Authors:  Xia Fan; Jun-Yu Zhu; Yu Sun; Li Luo; Jun Yan; Xue Yang; Jing Yu; Wan-Qi Tang; Wei Ma; Hua-Ping Liang
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

2.  Serum neutrophil gelatinase-associated lipocalin and proinflammatory cytokines in pigs with septic versus non-septic acute kidney injury.

Authors:  Hengjin Wang; Miao Zhang; Huijuan Mao; Zhixiang Cheng; Qingyan Zhang; Chunming Jiang; Chen Sun; Lingyun Sun
Journal:  Int Urol Nephrol       Date:  2014-11-25       Impact factor: 2.370

3.  Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats.

Authors:  Giuseppina Palladini; Marta Cagna; Laura Giuseppina Di Pasqua; Luciano Adorini; Anna Cleta Croce; Stefano Perlini; Andrea Ferrigno; Clarissa Berardo; Mariapia Vairetti
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-24

4.  Etoposide attenuates zymosan-induced shock in mice.

Authors:  M Remichkova; M Yordanov; P Dimitrova
Journal:  Inflammation       Date:  2007-10-09       Impact factor: 4.092

5.  Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome.

Authors:  Thomas J H Volman; R Jan A Goris; Jos W M van der Meer; Thijs Hendriks
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

6.  The Effects of Continuous Blood Purification for SIRS/MODS Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Tian Hongliang; Zeng Rong; Wang Xiaojing; Sun Rao; Li Lun; Tian Jinhui; Cao Nong; Yang Kehu
Journal:  ISRN Hematol       Date:  2012-09-26

7.  Inhibiting TNF-α signaling does not attenuate induction of endotoxin tolerance.

Authors:  Christopher Loosbroock; Kenneth W Hunter
Journal:  J Inflamm Res       Date:  2014-12-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.